Principal Consultant

Pauline McEwan, Ph.D., DABT, is a board-certified toxicologist by the American Board of Toxicology (ABT) with 20+ years of scientific and regulatory experience in multiple therapeutic areas. Dr. McEwan completed post-doctoral training in Harvard Medical School’s cardiovascular genetics department. It was followed by several senior industry positions developing advanced cell and gene biotherapeutics, small molecule, and combination products with device delivery platforms for cardiovascular diseases.

Over the years, Dr. McEwan expanded her expertise as a principal nonclinical consultant developing pharmaceuticals, advanced biotherapeutics (cell and gene therapies), and combination products for multiple disease indications with specific knowledge in regenerative medicine. She currently serves in a scientific advisory capacity on the Working Group Grants for the California Institute for Regenerative Medicine (CIRM).